DIANA technology is not limited to kinase inhibitor profiling. As a service, we can adapt any assay from our DIANA profiling portfolio into a robust high‑throughput screening (HTS) format. In this setup, screened compounds compete with the DIANA probe for target binding, enabling sensitive hit discovery with very low false‑positive and false‑negative rates. The assay directly delivers quantitative binding data (Kd) and supports efficient screening of pooled compound libraries, significantly reducing screening time and cost.
This makes our DIANA HTS screening service suitable both for large‑scale pharmaceutical screening projects and for smaller academic or biotech projects. For example, in‑house libraries of around 10,000 compounds can be screened by us using only a small number of 384‑well plates. In addition, we can offer downstream ADME characterization of lead compounds emerging from HTS campaigns.
Download the complete HTS Leaflet
Document name | Download |
|---|---|
Pick the library and send us your requirements
Our High-Throughput Screening (HTS) services provide access to diverse fragment-based libraries, which include low molecular weight and structurally varied molecules critical for identifying promising drug leads. We offer two main compound sets: the Lead-like Diversity Set and the Drug-like Diversity Set. Additionally, we provide focused libraries tailored for targeted screening, such as the Kinase Inhibitor Library and the FDA-approved Drug Library.
Clients can utilize our HTS services with any assay available in our inhibitor profiling portfolio or request a custom-designed assay tailored to their specific target and research objectives. Project timelines and pricing are highly dependent on the scope and requirements and are discussed and agreed upon individually.
This compound collection is designed to facilitate the discovery of novel active scaffolds. Hits from this library typically have low binding affinity (Kd > 1 µM), making them excellent starting points for further optimization and structure-activity relationship (SAR) studies.
Containing appx. 10,000 compounds (over 6,000 scaffolds)
Compounds with low MW (MW<400 Da) and logP (0-3)
No PAINS, only medchem friendly compounds
Containing appx. 120,000 compounds (over 20,000 scaffolds)
Compounds with mid MW (MW<500 Da) and logP (1-5)
No PAINS, only medchem friendly compounds
Drug Discovery Services
We can seamlessly convert any DIANA assay from our inhibitor profiling portfolio into a high-throughput screening (HTS) format. If your target is not currently covered in our DIANA assay portfolio, we can also custom-develop a DIANA assay tailored specifically to your needs. HTS utilizing DIANA technology offers sensitive hit discovery with a direct potency (Kd) readout and demonstrates exceptional robustness and reproducibility. This is evidenced by our typical Z' factors exceeding 0.7 in HTS campaigns. Moreover, our methodology supports efficient pooled library screening, which significantly reduces screening costs and time. This service is suitable for both pharmaceutical and academic projects, offering high sensitivity, reliability, and scalability for diverse research goals.
Our assays deliver robust and reproducible results across a wide range of targets, including those considered challenging. This reliability helps minimize project setbacks and ensures greater confidence in your screening outcomes.
We can establish and deliver high-throughput screening (HTS) services within 3 months. This accelerated setup significantly shortens early discovery timelines and allows you to quickly move from assay design to actionable results.
DIANA assays can be developed as stand-alone services tailored to your specific project needs, or seamlessly integrated into broader collaborative programs. This flexibility makes them suitable for both large pharma pipelines and smaller academic initiatives.
To support your project goals, we provide models with defined performance milestones and risk-sharing options. This ensures transparency, reduces upfront risk, and aligns our success directly with your discovery outcomes.
